Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
urofollitropin + human chorionic gonadotropin
- Development stage
- Unknown
- Lead developer
- Ferring Pharmaceuticals
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intramuscular, Subcutaneous
01
Overview
This combination therapy consists of **urofollitropin**, a highly purified form of follicle-stimulating hormone (FSH) extracted from human postmenopausal urine, and **human chorionic gonadotropin (hCG)**, a hormone that acts as an analog to luteinizing hormone (LH). The combination is primarily utilized in reproductive medicine to treat infertility. In women, urofollitropin stimulates the development of ovarian follicles, while hCG is administered to trigger final follicular maturation and ovulation. In men with hypogonadotropic hypogonadism, the combination is used to stimulate spermatogenesis; urofollitropin promotes the maturation of seminiferous tubules and germ cell development, while hCG stimulates the Leydig cells to produce testosterone. The provided context highlights its use as a traditional comparator for treating metabolic hypogonadism in men seeking fatherhood.
- Other names
- uFSH + hCGpurified FSH + human chorionic gonadotropin
02
Targets
FSHR (Follicle-stimulating hormone receptor)LHCGR (Luteinizing hormone/choriogonadotropin receptor)
Beyond the preview
Go deeper on urofollitropin + human chorionic gonadotropin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on urofollitropin + human chorionic gonadotropin.